DE63383T1 - Mittel zur krebsbehandlung. - Google Patents
Mittel zur krebsbehandlung.Info
- Publication number
- DE63383T1 DE63383T1 DE198282103316T DE82103316T DE63383T1 DE 63383 T1 DE63383 T1 DE 63383T1 DE 198282103316 T DE198282103316 T DE 198282103316T DE 82103316 T DE82103316 T DE 82103316T DE 63383 T1 DE63383 T1 DE 63383T1
- Authority
- DE
- Germany
- Prior art keywords
- agent
- group
- derivative
- treating cancer
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 7
- 201000011510 cancer Diseases 0.000 title claims abstract 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract 9
- 125000005427 anthranyl group Chemical group 0.000 claims abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 3
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000005995 Aluminium silicate Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000012211 aluminium silicate Nutrition 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 235000010216 calcium carbonate Nutrition 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56059153A JPS57175119A (en) | 1981-04-21 | 1981-04-21 | Agent for removing cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE63383T1 true DE63383T1 (de) | 1983-08-04 |
Family
ID=13105115
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE198282103316T Pending DE63383T1 (de) | 1981-04-21 | 1982-04-20 | Mittel zur krebsbehandlung. |
| DE8282103316T Expired DE3262943D1 (en) | 1981-04-21 | 1982-04-20 | Cancer treating agent |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8282103316T Expired DE3262943D1 (en) | 1981-04-21 | 1982-04-20 | Cancer treating agent |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4507309A (enExample) |
| EP (1) | EP0063383B1 (enExample) |
| JP (1) | JPS57175119A (enExample) |
| AT (1) | ATE12582T1 (enExample) |
| CA (1) | CA1204664A (enExample) |
| DE (2) | DE63383T1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2076012A1 (en) * | 1990-02-14 | 1991-08-15 | Yasuyuki Kato | Agent for inhibiting the formation of denatured ldl |
-
1981
- 1981-04-21 JP JP56059153A patent/JPS57175119A/ja active Granted
-
1982
- 1982-04-12 US US06/367,354 patent/US4507309A/en not_active Expired - Fee Related
- 1982-04-19 CA CA000401222A patent/CA1204664A/en not_active Expired
- 1982-04-20 DE DE198282103316T patent/DE63383T1/de active Pending
- 1982-04-20 AT AT82103316T patent/ATE12582T1/de not_active IP Right Cessation
- 1982-04-20 DE DE8282103316T patent/DE3262943D1/de not_active Expired
- 1982-04-20 EP EP82103316A patent/EP0063383B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US4507309A (en) | 1985-03-26 |
| DE3262943D1 (en) | 1985-05-15 |
| ATE12582T1 (de) | 1985-04-15 |
| JPS6366288B2 (enExample) | 1988-12-20 |
| CA1204664A (en) | 1986-05-20 |
| EP0063383B1 (en) | 1985-04-10 |
| JPS57175119A (en) | 1982-10-28 |
| EP0063383A1 (en) | 1982-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3876400T2 (de) | Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen. | |
| DE60107835T2 (de) | Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide | |
| DE69513708T2 (de) | Verwendung von 3,4-diphenyl chroman Derivaten zur Herstellung eines Medikaments zur Absinkung des Cholesterolspiegels | |
| DE69724108T2 (de) | Isochinolinderivate und arzneimittel | |
| EP2389937B1 (en) | Medicinal composition for improving brain function | |
| DE69127290D1 (de) | Arzneimittelfreisetzungssystem aus porphyrinzusammensetzungen und verfahren zu deren verwendung | |
| CA2105071A1 (en) | Use of nicotinic analogs for treatment of degenerative diseases of the nervous system | |
| JP2009542815A (ja) | Ｐｄｅ４の二環式ヘテロアリール阻害剤 | |
| DE04010435T1 (de) | Zolpidem Hemitartrat Solvat | |
| DE69434888T2 (de) | 5-ht4-rezeptor-antagonisten | |
| AU2003248024A1 (en) | Use of N-substituted-1,5-di deoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections | |
| DE69825286T2 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
| KR20250170695A (ko) | 메티오닌 아데노실트랜스퍼라제 2a(mat2a) 억제제 조합 및 이의 용도 | |
| DE69834500T2 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| DE69611452T2 (de) | Benzothiophenderivate | |
| EP0398720A3 (en) | Piperazine derivatives | |
| DE63383T1 (de) | Mittel zur krebsbehandlung. | |
| DE69718406T2 (de) | Strahlungsschutzmittel geignet zur Verwendung mit Radiopharmazeutika enthaltend reduzierbare aktive Inhaltsstoffe | |
| JPS6140288A (ja) | 医薬組成物 | |
| IL108433A0 (en) | Dtpa metal complex derivatives, pharmaceutical compositions containing the same, and methods for the preparation thereof | |
| US5652249A (en) | Method of treating depression | |
| ES2009689A6 (es) | Procedimiento para preparar derivados de 3-piperidina-carbaldehido-oxima. | |
| WO1991018886A1 (en) | Compounds for the treatment of age-related memory impairment and other cognitive disorders | |
| DE3906214A1 (de) | Verwendung von macrolactone als antiallergica | |
| US3743740A (en) | 3,6-dimethyl - 1,2,3,4,4a,9a - hexahydro-ypsilon-carboline dihydrochloride for treating mental diseases |